CAH logo

CAH
Cardinal Health, Inc.

3,387
Mkt Cap
$48.91B
Volume
4.25M
52W High
$233.60
52W Low
$120.72
PE Ratio
29.91
CAH Fundamentals
Price
$207.83
Prev Close
$210.92
Open
$211.11
50D MA
$217.05
Beta
0.31
Avg. Volume
1.68M
EPS (Annual)
$6.45
P/B
-17.01
Rev/Employee
$3.86M
$46,274.00
Loading...
Loading...
News
all
press releases
Procyon Advisors LLC Boosts Holdings in Cardinal Health, Inc. $CAH
Procyon Advisors LLC boosted its stake in shares of Cardinal Health, Inc. (NYSE:CAH - Free Report) by 78.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 17,025 shares of the company's stock after purchasing an additional 7,499 shares during the period. Pr...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
Cardinal Health, Inc. $CAH Shares Bought by Swiss Life Asset Management Ltd
Swiss Life Asset Management Ltd grew its position in Cardinal Health, Inc. (NYSE:CAH - Free Report) by 73.3% during the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·1d ago
News Placeholder
Cardinal Health (CAH) Stock Moves -1.47%: What You Should Know
Cardinal Health (CAH) concluded the recent trading session at $207.83, signifying a -1.47% move from its prior day's close.
Zacks·2d ago
News Placeholder
Here's Why You Should Retain AMN HealthCare Stock in Your Portfolio
AMN rides MSP momentum, AI investments and surging labor disruption demand, but pricing pressure and volatile healthcare trends cloud its near-term outlook.
Zacks·2d ago
News Placeholder
What Powers BWXT's Strength in Nuclear Medicine Manufacturing?
BWX Technologies expands beyond defense, boosting nuclear medicine with isotopes, new capabilities and a growing role in cancer diagnostics and treatment.
Zacks·2d ago
News Placeholder
GEHC Acquires Intelerad to Boost Cloud-First, AI Imaging Capabilities
GE HealthCare completes the $2.3B Intelerad deal to expand AI-driven imaging, boost recurring revenues and strengthen its cloud-first healthcare platform.
Zacks·2d ago
News Placeholder
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments
GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term growth.
Zacks·2d ago
News Placeholder
Here's Why You Should Add McKesson Stock to Your Portfolio Now
McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.
Zacks·2d ago
News Placeholder
Park National Corp OH Lowers Holdings in Cardinal Health, Inc. $CAH
Park National Corp OH decreased its position in Cardinal Health, Inc. (NYSE:CAH - Free Report) by 26.2% during the fourth quarter, according to the company in its most recent filing with the...
MarketBeat·2d ago
News Placeholder
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPK rides on RAYALDEE strength and partnerships, but revenue decline, losses, and reliance on a single drug cloud its near-term outlook.
Zacks·3d ago
<
1
2
...
>

Latest CAH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.